Literature DB >> 34095710

Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature.

M Zeeshan Ozair1, Alexandra M Giantini Larsen2, Juliana Eng3, Nelson S Moss2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34095710      PMCID： PMC8169075          DOI： 10.1200/PO.20.00485

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  23 in total

1.  A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.

Authors:  Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

Review 2.  A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Authors:  Tao Jiang; Chunxia Su; Shengxiang Ren; Federico Cappuzzo; Gaetano Rocco; Joshua D Palmer; Nico van Zandwijk; Fiona Blackhall; Xiuning Le; Nathan A Pennell; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 3.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

Review 4.  EGFR mutation status in brain metastases of non-small cell lung carcinoma.

Authors:  Fanny Burel-Vandenbos; Damien Ambrosetti; Michael Coutts; Florence Pedeutour
Journal:  J Neurooncol       Date:  2012-10-20       Impact factor: 4.130

5.  CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Authors:  Yi-Long Wu; Myung-Ju Ahn; Marina Chiara Garassino; Ji-Youn Han; Nobuyuki Katakami; Hye Ryun Kim; Rachel Hodge; Paramjit Kaur; Andrew P Brown; Dana Ghiorghiu; Vassiliki A Papadimitrakopoulou; Tony S K Mok
Journal:  J Clin Oncol       Date:  2018-07-30       Impact factor: 44.544

6.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Authors:  James Chih-Hsin Yang; Myung-Ju Ahn; Dong-Wan Kim; Suresh S Ramalingam; Lecia V Sequist; Wu-Chou Su; Sang-We Kim; Joo-Hang Kim; David Planchard; Enriqueta Felip; Fiona Blackhall; Daniel Haggstrom; Kiyotaka Yoh; Silvia Novello; Kathryn Gold; Tomonori Hirashima; Chia-Chi Lin; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

7.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Authors:  Peter Ballard; James W T Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S Thress; Pasi A Jänne; Darren Cross
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

8.  Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.

Authors:  Anita Mahajan; Salmaan Ahmed; Mary Frances McAleer; Jeffrey S Weinberg; Jing Li; Paul Brown; Stephen Settle; Sujit S Prabhu; Frederick F Lang; Nicholas Levine; Susan McGovern; Erik Sulman; Ian E McCutcheon; Syed Azeem; Daniel Cahill; Claudio Tatsui; Amy B Heimberger; Sherise Ferguson; Amol Ghia; Franco Demonte; Shaan Raza; Nandita Guha-Thakurta; James Yang; Raymond Sawaya; Kenneth R Hess; Ganesh Rao
Journal:  Lancet Oncol       Date:  2017-07-04       Impact factor: 41.316

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Authors:  Glenwood Goss; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Jong Seok Lee; Gee-Chen Chang; Lucio Crino; Miyako Satouchi; Quincy Chu; Toyoaki Hida; Ji-Youn Han; Oscar Juan; Frank Dunphy; Makoto Nishio; Jin-Hyoung Kang; Margarita Majem; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Tetsuya Mitsudomi
Journal:  Lancet Oncol       Date:  2016-10-14       Impact factor: 41.316
View more
  1 in total

1.  Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience.

Authors:  Joseph A Carnevale; Brandon S Imber; Graham M Winston; Jacob L Goldberg; Ase Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss
Journal:  J Neurosurg       Date:  2021-09-10       Impact factor: 5.408
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.